Citigroup Issues Pessimistic Forecast for Kenvue (NYSE:KVUE) Stock Price

Kenvue (NYSE:KVUE) had its price target dropped by equities research analysts at Citigroup from $20.00 to $17.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s target price suggests a potential upside of 1.95% from the company’s previous close.

Other equities research analysts have also issued reports about the stock. Rothschild Redb upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, September 26th. JPMorgan Chase & Co. lowered their price target on shares of Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a report on Friday, July 25th. Rothschild & Co Redburn upgraded shares of Kenvue from a “neutral” rating to a “buy” rating and lowered their price target for the company from $22.50 to $22.00 in a report on Friday, September 26th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kenvue in a report on Saturday, September 27th. Finally, Zacks Research upgraded shares of Kenvue to a “strong sell” rating in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $21.18.

Kenvue Trading Down 1.0%

Shares of KVUE opened at $16.68 on Thursday. The firm has a market cap of $32.00 billion, a price-to-earnings ratio of 22.53, a PEG ratio of 2.42 and a beta of 0.72. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. Kenvue has a fifty-two week low of $15.47 and a fifty-two week high of $25.17. The firm has a 50 day moving average price of $19.15 and a 200-day moving average price of $21.34.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business’s quarterly revenue was down 4.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities research analysts forecast that Kenvue will post 1.14 earnings per share for the current year.

Institutional Trading of Kenvue

A number of hedge funds and other institutional investors have recently modified their holdings of KVUE. Capital Investment Advisors LLC grew its position in shares of Kenvue by 16.4% in the 1st quarter. Capital Investment Advisors LLC now owns 13,261 shares of the company’s stock worth $318,000 after buying an additional 1,869 shares during the period. GAMMA Investing LLC grew its position in shares of Kenvue by 33.2% in the 1st quarter. GAMMA Investing LLC now owns 24,778 shares of the company’s stock worth $594,000 after buying an additional 6,169 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Kenvue by 4.8% in the 1st quarter. Assenagon Asset Management S.A. now owns 884,348 shares of the company’s stock worth $21,207,000 after buying an additional 40,447 shares during the period. CX Institutional purchased a new stake in shares of Kenvue in the 1st quarter worth about $185,000. Finally, Focus Financial Network Inc. grew its position in shares of Kenvue by 9.5% in the 1st quarter. Focus Financial Network Inc. now owns 12,624 shares of the company’s stock worth $303,000 after buying an additional 1,095 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.